Reference : The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and impr...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/10993/18333
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats.
English
Pelzer, Theo [> >]
Jazbutyte, Virginija [> >]
Hu, Kai [> >]
Segerer, Stephan [> >]
Nahrendorf, Matthias [> >]
Nordbeck, Peter [> >]
Bonz, Andreas W. [> >]
Muck, Jenny [> >]
Fritzemeier, Karl-Heinrich [> >]
Hegele-Hartung, Christa [> >]
Ertl, Georg [> >]
Neyses, Ludwig mailto [University of Luxembourg > Research Office]
2005
Cardiovascular research
67
4
604-12
Yes (verified by ORBilu)
International
0008-6363
Netherlands
[en] Animals ; Atrial Natriuretic Factor/metabolism ; Cardiomegaly/drug therapy/metabolism/pathology ; Estradiol/analogs & derivatives/metabolism/pharmacology/therapeutic use ; Estrogen Antagonists/pharmacology ; Estrogen Receptor alpha/agonists ; Female ; Gene Expression/drug effects ; Hemodynamics/drug effects ; Hypertension/metabolism/pathology ; Magnetic Resonance Imaging ; Models, Animal ; Myocardium/metabolism/pathology ; Myosin Heavy Chains/metabolism ; Organ Size ; Ovariectomy ; Papillary Muscles/drug effects ; Random Allocation ; Rats ; Rats, Inbred SHR ; Tamoxifen/metabolism/therapeutic use ; Ventricular Myosins/metabolism
[en] OBJECTIVE: Cardiac mass increases with age and with declining estradiol serum levels in postmenopausal women. Although the non-selective estrogen receptor-alpha and -beta agonist 17beta-estradiol attenuates cardiac hypertrophy in animal models and in observational studies, it remains unknown whether activation of a specific estrogen receptor subtype (ERalpha or ERbeta) might give similar or divergent results. Therefore, we analyzed myocardial hypertrophy as well as cardiac function and gene expression in ovariectomized, spontaneously hypertensive rats (SHR) treated with the subtype-selective ERalpha agonist 16alpha-LE2 or 17beta-estradiol. METHODS AND RESULTS: Long-term administration of 16alpha-LE2 or 17beta-estradiol did not affect elevated blood pressure, but both agonists efficiently attenuated cardiac hypertrophy and increased cardiac output, left ventricular stroke volume, papillary muscle strip contractility, and cardiac alpha-myosin heavy chain expression. The observed effects of E2 and 16alpha-LE2 were abrogated by the ER antagonist ZM-182780. Improved left ventricular function upon 16alpha-LE2 treatment was also observed in cardiac MRI studies. In contrast to estradiol and 16alpha-LE2, tamoxifen inhibited cardiac hypertrophy but failed to increase alpha-myosin heavy chain expression and cardiac output. CONCLUSIONS: These results support the hypothesis that activation of ERalpha favorably affects cardiac hypertrophy, myocardial contractility, and gene expression in ovariectomized SHR. Further studies are required to determine whether activation ERbeta mediates redundant or divergent effects.
http://hdl.handle.net/10993/18333
10.1016/j.cardiores.2005.04.035
http://cardiovascres.oxfordjournals.org/content/67/4/604.full.pdf+html

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats..pdfPublisher postprint352.35 kBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.